Samsung Biologics presented a customized process design case study for multi-target antibody therapeutics that reduced development time from 13 months to 9.5 months, a 27% reduction. The company also reported that its proprietary platform doubled production output and showcased S-Tensify, a culture-process enhancement platform. At the 2026 BioProcess International conference in Boston, Samsung Biologics promoted its full-cycle capabilities spanning contract research, development and manufacturing, while presenting strategies for controlling drug quality and efficacy from cell line development. The company also proposed new quality measurement standards for viral therapeutics at the concurrent Cell & Gene Therapy International Conference.